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High-resolution array comparative genomic hybridisation (aCGH) analysis of DNA copy number aberrations (CNAs) was performed
on breast carcinomas in premenopausal women from Western New York (WNY) and from Gomel, Belarus, an area exposed to
fallout from the 1986 Chernobyl nuclear accident. Genomic DNA was isolated from 47 frozen tumour specimens from 42 patients
and hybridised to arrays spotted with more than 3000 BAC clones. In all, 20 samples were from WNY and 27 were from Belarus. In
total, 34 samples were primary tumours and 13 were lymph node metastases, including five matched pairs from Gomel. The average
number of total CNAs per sample was 76 (range 35–134). We identified 152 CNAs (92 gains and 60 losses) occurring in more
than 10% of the samples. The most common amplifications included gains at 8q13.2 (49%), at 1p21.1 (36%), and at 8q24.21 (36%).
The most common deletions were at 1p36.22 (26%), at 17p13.2 (26%), and at 8p23.3 (23%). Belarussian tumours had more
amplifications and fewer deletions than WNY breast cancers. HER2/neu negativity and younger age were also associated with a
higher number of gains and fewer losses. In the five paired samples, we observed more discordant than concordant DNA changes.
Unsupervised hierarchical cluster analysis revealed two distinct groups of tumours: one comprised predominantly of Belarussian
carcinomas and the other largely consisting of WNY cases. In total, 50 CNAs occurred significantly more commonly in one cohort vs
the other, and these included some candidate signature amplifications in the breast cancers in women exposed to significant radiation.
In conclusion, our high-density aCGH study has revealed a large number of genetic aberrations in individual premenopausal breast
cancer specimens, some of which had not been reported before. We identified a distinct CNA profile for carcinomas from a nuclear
fallout area, suggesting a possible molecular fingerprint of radiation-associated breast cancer.
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The incidence of breast cancer in young women is lower
than in the postmenopausal age group. However, carcinomas
in these patients are generally more aggressive and associated
with poorer prognosis. The aetiology of premenopausal breast
cancer is not clear. In a minority of patients, tumours develop
on the basis of germline mutations in the BRCA1 and BRCA2
genes. Environmental exposure variables have been extensively
studied as a causative factor of human mammary neoplasia. There
is significant evidence, derived from diverse populations, that
ionising radiation can cause breast cancer. Some examples
are patients who received therapeutic radiation to the chest
early in life for Hodgkin’s disease (HD), patients who were treated
with radiation for mastitis and other benign breast diseases,
patients who received thymic irradiation, patients who underwent
frequent fluoroscopies for pulmonary disease, and atomic
bomb survivors (Behrens et al, 2000; Clemons et al, 2000; Gaffney
et al, 2001; Land et al, 2003; Travis et al, 2003). Among these,
the best-studied group are women who developed breast cancer
after treatment for HD. It was reported that the risk of developing
breast cancer was greatest if patients were treated under the
age of 30, and hormonal stimulation of the irradiated breast
tissue appeared to play an important role (Clemons et al,
2000; Travis et al, 2003). The risk clearly was dose dependent
(Travis et al, 2003), and the median latency period was in the
range of 15 years (Clemons et al, 2000). Similar observations
held true for the Japanese atomic bomb survivors. Breast cancer
risk was inversely related to age at exposure, there was a
linear dose response, and the minimum latency period was 12
years (Land et al, 2003). Tumours arising in irradiated women
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smay be associated with reduced overall survival (Gaffney et al,
2001).
Researchers at Roswell Park Cancer Institute (RPCI), including
some of the authors of this paper, have been actively involved
in several epidemiologic studies on a more recent group of
probands, namely individuals exposed to radiation released by
the 1986 Chernobyl nuclear accident (Mahoney et al, 2004).
Although the reactor was located in Ukraine, neighbouring
Belarus received about 70% of the radioactive fallout (Ermak
et al, 2003). It is well documented that children exposed to that
fallout have an increased cancer rate (Peterson et al, 1997). One of
the most common radiation-induced malignancies is papillary
carcinoma of the thyroid, and this tumour type was shown to
harbour molecular abnormalities that differed from those in
sporadic thyroid cancers (Tuttle and Becker, 2000; Ermak et al,
2003). There also was an increase in breast cancer incidence in
parts of Belarus after the Chernobyl accident, especially in rural
areas and in premenopausal women (Sasnouskaya and Okeanov,
2000).
In theory, breast carcinomas associated with ionising radiation
should facilitate insight into the molecular pathogenesis of early-
onset breast cancer, yet few such studies have been published. In
one paper, post-HD breast carcinomas were found to have more
microsatellite alterations compared to sporadic tumours (Behrens
et al, 2000). In another group of post-HD breast cancer patients,
there were no significant differences compared with sporadic cases
with regard to BRCA1, BRCA2, oestrogen receptor (ER), PR, HER2
and p53 status (Gaffney et al, 2001). Several in vitro studies are
of relevance. It was shown that human mammary epithelial cells
(HMEC) in culture can be transformed by g-irradiation (Wazer
et al, 1994). Subsequent studies showed that radiation induced
nonrandom chromosomal changes in HMEC (Durante et al, 1996;
Yang et al, 1997). Finally, irradiation of nontransformed MCF-10F
cells led to altered expression of 49 of 190 genes assayed (Roy et al,
2001).
Comparative genomic hybridisation (CGH) is one tool to
investigate the molecular pathology of human tumours. Conven-
tional CGH is based on competitive in situ hybridisation of normal
metaphase spreads by two differentially labelled whole genomic
DNAs, one derived from tumour tissue and the other from a
normal reference. Regions of altered DNA copy number (losses
and gains) in the tumour are quantitated as ratio changes along
metaphase chromosomes. The resolution of this technique is in
the range of 10–20Mb. In this study, we have used array CGH
to obtain better resolution to facilitate identification of novel
candidate breast cancer genes. High-density bacterial artificial
chromosome (BAC)-based arrays developed at RPCI were
employed to screen for DNA copy number gains and losses in
premenopausal breast cancers from two geographically distinct
areas in an attempt to identify genetic changes that may be specific
to early-onset tumours and/or radiation exposure.
MATERIALS AND METHODS
Tissues
In all, 55 frozen samples of breast cancers were obtained from
premenopausal patients from Western New York (WNY) and
Belarus. Samples from Belarus were collected and snap frozen
between August 2002 and January 2003. The tumours were
collected from women who resided in the Gomel area since April
1986. They were transported on dry ice to the United States and
processed at RPCI. The WNY samples were obtained through the
tissue procurement facility at RPCI. Patients with a strong family
history of breast cancer and cases with known BRCA1/2 mutations
were excluded. This study was approved by the RPCI Institutional
Review Board. All samples were evaluated morphologically and
only those with more than 50% tumour cellularity were included.
Preliminary experiments had shown that 430% tumour cellularity
was sufficient. Duplicate assays and dye swapping experiments
were performed for a subset of samples, showing very good
reproducibility. Genomic DNA was extracted from all samples
using TriZol (Invitrogen, Grand Island, NY, USA). In total, 47
samples met the quality criteria and were included in the final
analysis. Patient characteristics are shown in Table 1. All Gomel
patients were Caucasian, as were the great majority of RPCI
patients (except for two African American women). The age of the
patients ranged from 24 to 50 years. There were 34 primary
tumours and 13 lymph node metastases. This cohort included five
paired cases from Belarus.
Her2 protein expression assays
The immunohistochemical assay for Her2 expression in formalin-
fixed, paraffin-embedded tumour sections followed the Herceptest
protocol (Dako, Carpinteria, CA, USA), and the stains were scored
from 0 and 1þ (negative) to 2þ and 3þ (positive), using
recommended guidelines. For Western blotting, 50mg of protein
was used per sample (extraction from tissue utilized the TriZol
protocol). Protein was resolved over 8% SDS–PAGE and
transferred to a PVDF membrane. The blot was blocked in
blocking buffer (5% nonfat dry milk, 10mM Tris (pH 7.5), 10mM
NaCl, and 0.1% Tween-20) for 1h at room temperature. The
membrane was then incubated with the Herceptest antibody
(Dako) at a dilution of 1:500 at 41C overnight. This was followed
by incubation with a goat anti-mouse horseradish peroxidase-
conjugated secondary antibody (KPL, Gaithersburg, MD, USA) at
a dilution of 1:5000 at room temperature for 1h. Protein bands
were visualised by the SuperSignal West Pico Chemiluminescent
Substrate kit obtained from PIERCE (Rockford, IL, USA) and
exposed with Kodak X-Ray film.
Table 1 Patient characteristics
WNY Belarus P-value
Age (median, years) 41.5 45.5
p43 12 10 0.23
443 8 12
Caucasian 18 22
African American 2 0 0.43
Histology
Ductal 17 20
Lobular 2 0 0.29
Other/unknown 1 2
Grade
1–2 7 5
3 13 14 0.81
Unknown 0 3
Size
T1 4 8
T2–T4 16 12 0.30
Unknown 0 2
LN status
Negative 6 5 0.85
Positive 14 17
Stage
I2 4
II 11 12 0.71
III 7 6
WNY¼Western New York; LN¼lymph node.
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The CGH arrays were prepared in the Microarray Core Facility at
RPCI according to established protocols (Snijders et al,
2001; Cowell and Nowak, 2003; Cowell et al, 2004a). A total of
3084 BAC clones were common to all arrays used in this series
of experiments (average resolution B1Mb). The WNY and
Belarussian samples were coded and then assayed concurrently
and blindly. Genomic DNA (0.5mg) was fluorescently labelled
by random priming in a 100ml reaction containing the DNA,
random primers solution, appropriate buffers and Cy3- or Cy5-
dCTP-labelled nucleotides. Labelling occurred with the addition
of appropriate agents and incubation overnight at 371C. Arrays
were hybridised with appropriate solutions for 16h. Slides were
washed, dried and immediately scanned using an Affymetrix
428 scanner (Cowell et al, 2004b). Image analysis was performed
using the ImaGene version 4.1 software from BioDiscovery
Inc. The reference was pooled normal male DNA. Output
of the image analysis was processed by an in-house Perl program
to calculate log-transformed and normalised mean ratios of
test to reference fluorescence intensities. Any BAC that had
less than two replicates flagged as good or a standard error
greater than 0.15 was excluded. Map positions were identified
by querying the human genome sequence (July 2003 Build) at
http://genome.ucsc.edu. A sample output showing intensity ratios
across the whole genome for an individual tumour is shown in
Figure 1.
Data analysis
Copy number aberrations (CNAs) were determined at the clonal
level for each individual coded sample in a blinded manner. The
genome-wide mean and standard deviation of the log ratios were
calculated for the autosomal chromosomes and the X chromosome
separately. Thresholds for amplification and deletion were set
at two standard deviations from the mean in both directions.
Contiguous regions of amplification or deletion were identified by
flagging clones on the array based on adjacent chromosomal
locations. Recurrent amplifications and deletions were determined
by the frequency of these events among all samples or within
specific groups.
Unsupervised hierarchical clustering was performed using the
TIGR Multi-experiment Viewer (MeV version 2.2) software (Saeed
et al, 2003). Only clones that were included in at least 45 of 47
samples were considered. A filtered set of 202 clones with a high
variability across all samples (standard deviation/mean40.3) was
used for the hierarchical clustering. Clusters were generated using
the average linkage method with Pearson’s correlation coefficient
as the similarity metric.
Association between groups was tested from contingency tables
using the w
2 Pearson statistic. Resulting P-values are shown as
appropriate.
RESULTS
In all, 47 samples that met all quality control criteria including
tumour cellularity and patient age were included in the final
analysis. Patient charactertistics are shown in Table 1.
The two groups from WNY and Gomel were well matched for
ethnic background, age, extent of disease (tumour size, nodal
involvement, stage), tumour histology, grade and ER status.
The average number of CNAs in the breast carcinomas was 76
(37 gains and 39 losses). Tumours from WNY, older patients,
and HER2-positive cancers had more deletions and fewer
amplifications than tumours from Belarus, younger patients,
and HER2-negative cancers, respectively (Table 2). Primary
tumours and lymph node metastases, smaller and larger tumours,
0
0.5
1
1.5
2
2.5
3
3.5
4
Figure 1 aCGH of a representative tumour. DNA from a primary breast cancer was hybridised with normal male reference DNA. The whole genome is
arranged along the x-axis from left (1p) to right (X, Y). The chromosomal boundaries are indicated by vertical lines. The y-axis is linear. A number of distinct
amplifications (e.g. 3q, 9q, 11) and deletions (16q) as well as larger regions of DNA copy gains (e.g. 1q) and losses (11q, 22q) are easily recognised.
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sERþ and ER  cases, and carcinomas with and without associated
nodal metastases had comparable frequencies of copy number
gains and losses.
A representative diagram of genome-wide amplifications and
deletions is shown in Figure 1. Most breast cancers displayed both
distinct single BAC amplifications and deletions as well as broader
areas of DNA gains and losses. A total of 152 CNAs occurred in
more than 10% of samples, including 92 copy number gains and 60
losses. The majority of DNA gains (72%) were on the long arms
of chromosomes 1 and 8. Most of them were gains of one or two
copies, but a subset was higher level amplifications (three copies or
more, Table 3). The most common amplifications were at 8q13.2
(49%), at 1p21.1 (36%), and at 8q24.21 (36%). Gains at loci
containing the well-known breast oncogenes c-myc (at 8q24.21),
HER2 (at 17q21.1), and cyclin D1 (at11q13.3) were also frequent
(26, 19, and 13%, respectively) (Table 3). In an initial validation
experiment, HER2 amplification detected by array CGH was
correlated with protein expression using immunohistochemistry
and Western blot analysis (Figure 2). Amplified tumours showed
high levels of the Her2 oncoprotein, while nonamplified cases
were negative. While the majority of chromosomal gains had
previously been described, we identified seven novel recurrent
gains (as indicated in Table 3), five of which were in areas on 8q
that had not been reported to be common amplification sites in
breast cancer.
The largest number of DNA losses was on chromosome 17. In
most instances, one allele was lost, but possible homozygous
deletions were also observed (Table 4). The most common
deletions were at 1p36.22 (26%), at 17p13.2 (26%), and at 8p23.3
(23%). We identified nine novel recurrent losses, seven of which
were on chromosome 22 (Table 4).
In the five paired samples, some genetic changes were common
to the primary tumour and the lymph node metastasis. The
number of shared changes varied markedly from case to case.
However, all cases were characterised by a large number of
discordant CNAs. Metastatic tumours consistently developed more
gains than losses (Table 5).
Unsupervised hierarchical clustering using 202 discriminating
BAC clones produced a dendrogram with two distinct arms:
one predominantly composed of WNY carcinomas and the
other mostly comprised of Belarussian samples (Po0.001)
(Figure 3). These two arms were not significantly different
with regard to patient age, primary tumours vs metastases, tumour
size, nodal status, stage, grade, ER, or HER2 status. A total of 50
BAC clones were differentially amplified or deleted in premeno-
pausal breast cancers from WNY and Belarus, and 25 of these
contained named genes (Table 6). Of particular interest were 10
BAC clones that were amplified selectively in Belarussian tumours.
Moreover, three of these BACs were specifically deleted in WNY
Table 2 Distribution of CNAs
Average
gains
Average
losses
Average
total CNAs
WNY 32
a 44 76
Belarus 42
a 35 77
Age under median (p43) 43
b 33
c 76
Age over median (443) 33
b 45
c 78
Small tumours (T1) 39 36 75
Large tumours (T2–T4) 37 40 77
Lymph node negative 39 37 76
Lymph node positive 35 41 76
Primary tumours 37 41 78
Lymph node metastases 40 33 73
ER positive 31 49 80
ER negative 37 37 74
HER2 negative 41
d 35 76
HER2 positive 28
d 46 74
Total 37 39 76
CNA¼copy number aberrations; WNY¼Western New York.
aP¼0.034.
bP¼0.039.
cP¼0.054.
dP¼0.037.
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Figure 2 HER2 amplification and overexpression. Nine tumours from eight patients showed amplification at 17q21. The chromosome 17 aCGH profiles
of four of them are shown at the top along with one nonamplified sample (the y-axis is on a log2 scale). This was associated with Her2 protein
overexpression by immunohistochemistry (middle) and Western blot analysis (bottom).
Array CGH analysis of premenopausal breast cancer
G Varma et al
702
British Journal of Cancer (2005) 93(6), 699–708 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sTable 3 Recurrent gains arranged by chromosomal location (n¼92)
BAC clone
(RP11-) Chr. loc. #Samples (%)
#Samples with
X3 copy gains Genes
727M5 1p21.1 17 (36) 0
35B4 1q21.1 10 (21) 1 AB033071, AF379633, AF379636, LOC64182, AK075065
439A17 1q21.1 9 (19) 1 BC034024
196G18 1q21.2 5 (11) 1
307C12 1q22 5 (11) 1
120D12 1q23.1 8 (17) 0 FCRH1, CD5L, AF329488
452O22 1q23.1 8 (17) 1 SPTA1, AF060556, M11049
520H16 1q23.1 7 (15) 0
223F11 1q23.3 8 (17) 1 DDR2
403P14 1q23.3 8 (17) 0
506O24 1q23.3 8 (17) 0
572K18 1q23.3 8 (17) 0
404F10 1q23.3 7 (15) 0 SLAMF1, CD48, SLAMF7
528G1 1q23.3 6 (13) 0
80D6 1q24.1 6 (13) 0 LMX1A
54B9 1q24.1 5 (11) 0
162H11 1q25.2 6 (13) 1 RASAL2
317P15 1q25.3 5 (11) 1 RGS16, RGS8
335O13 1q32.1 8 (17) 1 PPFIA4, MYOG, FMOD, MYBPH, CHIT1
148K15 1q32.1 6 (13) 1 MDM4, LRRN5
294K24 1q32.1 6 (13) 1 PTPN7, ARL10B
150L7 1q32.1 5 (11) 0 PKP1, DKFZp434B1231
243M13 1q32.1 5 (11) 0 ABO18299, CNTN2
564A8 1q32.2 9 (19) 1 IL20, IL24, TOSO, MGC4309, MGCPIGR, FKSG87, AY063126
167J2 1q32.2 8 (17) 0 AY320401
328D5 1q32.2 7 (15) 3 CD34
357P18 1q32.2 5 (11) 0
35C1 1q32.2 5 (11) 1 CR1, CR2
211K12 1q41 5 (11) 0
35D17 1q41 5 (11) 0 PTPN14
115K6 1q43 7 (15) 1
182B22 1q43 6 (13) 0
150L22 1q44 9 (19) 2 AKT3, SDCCAG8, BC019085
194A15 3q25.31 5 (11) 1 TIPARP
88L18 5p15.1 5 (11) 0
36H5 5p15.31 5 (11) 0 AK090679
43B19 6q26 8 (17) 1 LPA
90P13 7p22.3 7 (15) 1
331D5 7q36.3 11 (23) 4 DNAJB6, PTPRN2
83O14 8q11.23 9 (19) 2 ST18
182B21 8q12.3 8 (17) 1
252M13 8q12.3 6 (13) 2
566L6 8q13.2 23 (49) 0 AB095942
120N14 8q13.3 5 (11) 1 SULF1
65J24 8q21.11 9 (19) 1
203C23 8q21.11 6 (13) 0 LY96
531A24 8q21.11 5 (11) 1
594N15 8q21.12 9 (19) 3 PKIA
79H23 8q21.12 8 (17) 3 IL7, CGI-62
93J13 8q21.12 8 (17) 1
523D2 8q21.12 7 (15) 3
80C11 8q21.13 14 (30) 3 FABP5, BT007449
214E11 8q21.13 10 (21) 2 TPD52
93E11 8q21.13 8 (17) 3
219B4 8q21.2 5 (11) 1 E2F5, BC030701, AK056185
480D6 8q21.3 12 (26) 3 MMP16, DKFZp761D112
435I11 8q21.3 12 (26) 3 NBS1, DECR1, C8orf1
122C21 8q21.3 8 (17) 2 CBFA2T1
118O8 8q21.3 5 (11) 1 CBFA2T1
413N8 8q22.1 10 (21) 2 SDC2, AF119386, AF107833
30J11 8q22.1 7 (15) 2 CDH17, RAD54B
700M17 8q22.1 7 (15) 2 CDH17, GEM
27I15 8q22.1 6 (13) 2
347C18 8q22.1 6 (13) 2 FLJ20530, TP53INP1
498C11 8q22.1 5 (11) 2
125O21 8q22.2 13 (28) 3 STK3, KCNS2, BC034778
131D12 8q22.2 7 (15) 1
208E21 8q22.2 6 (13) 1 COH1
680F3 8q22.3 6 (13) 1
12K18 8q22.3 5 (11) 1 ODF1, TIEG
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scases. Two BAC clones with known genes were significantly more
often amplified, and 13 were more frequently deleted in WNY
tumours.
DISCUSSION
There is a paucity of data on genomic changes in early-onset
breast cancer. The study reported here benefitted from a unique
population, namely premenopausal women from Belarus who were
exposed to significant fallout radiation from the 1986 Chernobyl
nuclear accident. It has been suggested that Chernobyl-related
cancers may be the best model to study the carcinogenic effect of
low-dose radiation (Ermak et al, 2003). We were able to compare
the genomic abnormalities in the Belarussian cancers to those in
similar tumours from a nonexposed area that were well matched
for ethnic background, age, tumour characteristics, and extent of
disease.
By utilising high-density aCGH technology with the capacity
to screen for DNA copy changes across the entire genome
at high resolution, we identified a larger number of chromosomal
abnormalities than previous breast cancer studies. Links to
genomic databases helped to identify candidate genes for further
investigation. A small number of published studies applied
aCGH technology to breast cancer cells, but only to a very limited
extent (Pinkel et al, 1998; Albertson et al, 2000; Kauraniemi
et al, 2001; Hyman et al, 2002; Pollack et al, 2002; Lage et al, 2003).
Almost all of these utilised a significantly smaller number
of specimens. Some of them focused only on cell lines (Hyman
et al, 2002; Lage et al, 2003) or on individual chromosomes (Pinkel
et al, 1998; Albertson et al, 2000; Kauraniemi et al, 2001).
We are not aware of any published reports on array or
conventional CGH analysis of DNA abnormalities in irradiated
cells. Likewise, our study may be the first to screen for somatic
genetic changes specifically in premenopausal tumours, providing
new insight into the molecular pathology of early-onset breast
cancer. The average number of total CNAs in our cohort of
tumours was 76 (range 35–134), which is approximately eight
times the average number of CNAs in breast cancers detected by
conventional CGH (Isola et al, 1995; Kuukasja ¨rvi et al,
1997; Aubele et al, 2000a,b; Zudaire et al, 2002), demonstrating
the superior sensitivity of our assay. This is in keeping with the
density of the BAC arrays used (some 3000 elements, average
resolution B1Mb).
Several groups have used conventional CGH to probe for genetic
aberrations in invasive breast carcinomas. Tirkkonen et al (1998)
found that the pattern of chromosomal gains and losses depended
on tumour size, grade, and receptor status. They described gain on
1q as an early event and gain on 8q as a marker for advanced
breast cancers. We have identified similar recurrent gains on 1q
and 8q, which were the most commonly affected chromosomal
arms in our series (Table 3). In a study of T2 (42cm) node-
negative breast cancers, a high overall number of genetic
aberrations was correlated with poor prognosis, and an increased
copy number at 8q and 20q13 indicated an aggressive phenotype
(Isola et al, 1995). Another similar study of invasive ductal
carcinomas found that gains on 1q, 11q, 17q, and 20q were
associated with poor prognosis (Zudaire et al, 2002). These DNA
changes were common in our series as well, and this observation
is in agreement with the more aggressive clinical course of
premenopausal breast cancer. Nine of 47 tumours showed
amplification of a BAC clone including HER2. This copy gain rate
(19%) is in keeping with numerous previous studies on HER2
amplification in breast cancer and proved to be among the most
common abnormalities in our study. Additional commonly
amplified BACs included the well-known breast cancer oncogenes
c-myc (at 8q24.21) and cyclin D1 (at 11q13.3), further demonstrating
adequate sensitivity of our method. Novel recurrent CNAs with
potential target genes included gains at 3q25.31, 6q26, 7q36.3,
13q32.2, and 16p11.2 (Table 3). Seven recurrent amplification loci,
most of which were found on 8q, had not been reported to be
frequent events in breast carcinomas.
Recurrent deletions were less common, and no single event was
found in more than 26% of the samples. Losses were most
frequently observed on chromosome 17, which is in keeping with
published cytogenetic data. However, nine of the remaining
recurrent deletions, including seven on chromosome 22, had not
been reported before (Table 4). Potential target genes included
Table 3 (Continued)
BAC clone
(RP11-) Chr. loc. #Samples (%)
#Samples with
X3 copy gains Genes
762A3 8q23.3 8 (17) 3 TRPS1
150N13 8q24.13 7 (15) 1
229L23 8q24.13 7 (15) 1
145G10 8q24.21 17 (36) 5
237F24 8q24.21 12 (26) 3 MYC
128G18 8q24.21 9 (19) 2
184M21 8q24.22 13 (28) 0 TG, SLA
316E19 8q24.22 12 (26) 0 TG, SLA, S40807
28A4 8q24.23 5 (11) 0 PFKP, PITRM1, BC021698
298E9 10p15.2 8 (17) 1
120P20 11q13.3 13 (28) 4
300I6 11q13.3 6 (13) 3 CCND1, FGF19
91P18 11q13.4 9 (19) 1
461N23 13q32.2 6 (13) 1 GPR18, EB12
455F5 16p11.2 5 (11) 0 ALDOA, TBX6, CORO1A
521P1 17q11.2 5 (11) 1 CCL8, CCL13, CCL1
94L15 17q21.1 9 (19) 7 ERBB2, STARD3, TCAP, PNMT, CAB2, GRB7, ZNFN1A3, MGC14832, BT006964
209H21 20p11.23 5 (11) 1 CSRP2BP, ZNF133
17F3 20q12 5 (11) 1 PTPRT
465L10 20q13.12 5 (11) 0 PLTP, ZNF335, SLC12AA5
560A15 20q13.31 5 (11) 1
181G18 21q21.1 6 (13) 0
Chr. loc.¼chromosomal location. Bold abnormalities indicate previously undescribed recurrent gains. Shaded rows indicate the same chromosomal band.
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signalling pathway (Mao et al, 2002).
It is conceivable that the novel chromosomal gains and losses
described here may be the hallmark of premenopausal breast
cancer. While our high-density BAC arrays appeared to have
adequate sensitivity, an initial validation experiment suggested
that the detected abnormalities may also be specific and verifiable
by alternate techniques. The tumours with amplification of the
Table 4 Recurrent losses arranged by chromosomal location (n¼60)
BAC clone
(RP11-) Chr. loc.
#Samples
(%)
#Samples with possible
homozygous deletions Genes
6B16 1p31.1 8 (17) 0
238O13 1p34.3 5 (11) 0 THRAP3
104J13 1p35.2 5 (11) 1
4O6 1p35.3 5 (11) 1 FGR, G1P3, MGC34648
692J20 1p35.3 5 (11) 0 PTAFR, DNAJC8, ATP1F1, SESN2
285H13 1p36.11 6 (13) 2
426M1 1p36.22 12 (26) 2 TNFRSF8, TNFRSF1B, BC042167
21N6 2q24.3 10 (21) 0
425J9 3p21.31 7 (15) 0 MYL3, PTHR1, HYPB
745J15 7p11.2 7 (15) 2 PSPH, CCT6A, SUMF2, PHKG1
148K1 7q36.1 9 (19) 0 ACCN3, FASTK, ABCB8, ASB10, CDK5
89M8 8p21.2 7 (15) 1 RHOBTB2, TNFRSF10B
232J22 8p21.2 5 (11) 0 BNIP3L
288N10 8p21.2 5 (11) 0
110I16 8p21.3 9 (19) 0
235I5 8p23.1 5 (11) 0 GATA4, FDFT1, NEIL2
240A17 8p23.3 11 (23) 0 DLGAP2
181G12 9p21.1 8 (17) 0
228B15 9q34.11 9 (19) 0 SH2D3C, CDK9, FPGS, ENG
104F15 10q22.1 5 (11) 1 LRRC20, EIF4EBP2, NODAL
37L21 10q24.31 7 (15) 0 PEO1, MRPL43, SEMA4G, BC053373
892K21 11q23.3 10 (21) 0
238I24 14q32.33 5 (11) 2
16O9 15q15.1 6 (13) 2 OIP5, ANKT, CIA30, ITPKA, LTK, KIAA0252
442O1 16q24.1 10 (21) 0 ZDHHC7, KIAA0513, BC030280
9A21 17p13.1 8 (17) 1 SENP3, EIF4A1, MPDU1, CD68, SSAT2, SHBG, FXR2, AK027742, BC006380
104H15 17p13.1 6 (13) 0 CENTB1, TNK1, NLGN2, FGF11, POLR2A, CHRNB1, KAISO-L1, PLSCR3,
MGC40107, BC040900
1D5 17p13.1 5 (11) 0 ALOX12B
89A15 17p13.1 5 (11) 0 RPL26, MYH10
231G16 17p13.2 11 (23) 2
208J12 17p13.2 12 (26) 4 TRPV3, CARKL, CTNS
61B16 17p13.3 11 (23) 1 CT120, GEMIN4
216P6 17p13.3 9 (19) 0 ABR, NXN, TIMM22
26N16 17p13.3 7 (15) 0 CGI-150, TIMM22
433M14 17p13.3 6 (13) 0
4F24 17p13.3 6 (13) 0 RPA1
356I18 17p13.3 5 (11) 0
818O24 17p13.3 5 (11) 0
73F15 17q11.2 6 (13) 1 CRLF3
58O9 17q21.2 5 (11) 1 GJC1, CTEN
266I24 17q21.31 8 (17) 4 PSME3, AOC2, AOC3, G6PC, RPL27, IFI35, AK055784
506G7 17q21.31 7 (15) 1
36J16 17q21.32 10 (21) 0 HOXB13, NDP52, FLJ35808
388C12 17q25.3 7 (15) 0
121I1 19p13.12 7 (15) 2 TPM4, HSH2, AP1M1, KIP3, MEL, FLJ25328, DKFZP586O0120, BT007184
56K21 19p13.12 5 (11) 2 CD97, DDX39, PRKCL1
298C17 19p13.2 8 (17) 0 EIF3S4, DNMT1, P2RY11
31N2 19p13.2 6 (13) 1 KIAA1198
283B8 19q13.2 9 (19) 1
2J15 19q13.32 7 (15) 1 CALM3, GNG8, PTGIR
236B14 19q13.33 7 (15) 0
17I20 19q13.33 5 (11) 2 SULT2B1, RPL18, SPHK2, DBP, CA11, FUT2
87L13 19q13.42 6 (13) 1
36N5 22q11.21 5 (11) 1 SDF2L1
213L15 22q12.1 7 (15) 1 KREMEN1
5O6 22q12.1 5 (11) 1
206B19 22q13.2 5 (11) 1 SREBF2
49M22 22q13.31 7 (15) 1 ARHGAP8
61L22 22q13.31 6 (13) 0 SMC1L2, FLJ20635
1113I2 22q13.33 5 (11) 0 MLC1, MOV10L1, PANX2
Chr. loc.¼chromosomal location. Bold abnormalities indicate previously undescribed recurrent losses. Shaded rows indicate the same chromosomal band.
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while the nonamplified tumours showed no immunoreactivity
(Figure 2).
Our series included five matched pairs of primary tumours and
nodal metastases from Belarus. As expected, a number of
chromosomal abnormalities were common to both the metastasis
and the parental tumour, although the number of shared CNAs
varied significantly from case to case (Table 5). Importantly, all
cases were characterised by a large number of discordant events.
Primary tumours developed a smaller, larger, or similar number of
CNAs compared to the secondary lesions. They tended to have
more deletions than losses. In contrast, nodal metastases
consistently were marked by a larger number of amplifications
over deletions. These findings suggest that metastases may form
at variable points in the evolution of a breast cancer, and that
primary tumour and metastasis independently develop additional
genetic changes. This adds to the growing body of evidence that
metastatic breast cancers may be biologically distinct from their
parental tumours.
As detailed in Table 2, the genetic changes were not evenly
distributed among the premenopausal breast cancers. While
chromosomal gains and losses were not dependent on tumour
site or size, nodal involvement, or ER status, younger age and
HER2 negativity were associated with a smaller number of
deletions and more amplifications. Likewise, tumours from Belarus
had more DNA gains and fewer deletions than carcinomas from
WNY. One of the most interesting observations was that breast
cancers from Gomel had a DNA profile that was distinct from that
of an age- and stage-matched control group treated at RPCI.
Strikingly, when all 47 cases were subjected to unsupervised
hierarchical clustering, two distinct groups emerged: one mostly
comprised of Belarussian breast cancers and one mainly com-
prised of cases from WNY (Figure 3). This segregation was
statistically highly significant (Po0.001). All of the other variables
(age, extent of disease, grade, receptor status) were similarly
distributed in the two arms. In all, 50 BAC clones were
differentially amplified or deleted in the two groups of tumours,
and half of these contained named genes. In total, 10 chromosomal
gains were specific to the Belarussian samples, and it is tempting
to speculate that these may represent the molecular hallmark of
radiation associated breast cancer. Potential target genes included
the MDM2-related gene MDM4 (at 1q32.1) and SULT1A3 (at
16p11.2) encoding an enzyme involved in the metabolism of
catecholamines and related compounds (Hildebrandt et al, 2004).
WNY tumours were characterised by a significantly higher number
of deleted BAC clones. It is unclear whether the chromosomal
Table 5 Copy number gains and losses in paired primary breast cancers
and their nodal metastases
Genetic changes
common to both primary
and metastasis
Discordant genetic
changes
In primary
only
In nodal
metastasis
only
Paired case # Gains Losses Gains Losses Gains Losses
1 63 (33) 9 (7) 16 (11) 9 (8) 30 (25) 12 (11)
2 19 (13) 10 (7) 21 (15) 26 (25) 31 (30) 15 (13)
3 20 (11) 1 (1) 48 (38) 37 (30) 42 (35) 22 (20)
4 7 (5) 9 (5) 25 (20) 34 (31) 36 (33) 24 (23)
5 13 (7) 0 (0) 13 (12) 91 (63) 42 (29) 4 (3)
Number of amplified or deleted BAC clones (number of affected chromosomal
bands in parentheses).
Figure 3 Cluster analysis (dendrogram). Unsupervised hierarchical
clustering based on 202 BAC clones (vertical) yielded two main arms
(horizontal): 26 tumours predominantly from Belarus (blue) on the left and
21 tumours mainly from WNY (red) on the right.
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pathogenesis or merely markers of genomic susceptibility to
radiation damage. There are no associated epidemiologic or
dosimetry data for the individual samples from Belarus so that,
at this juncture, we cannot be sure that the specific changes in the
tumour DNA are in fact due to radiation exposure. While the
Belarussian population is ethnically homogeneous (Ermak et al,
2003), and while the racial background of the breast cancer
patients from the Gomel area was similar to that in the WNY
cohort, we cannot rule out that other endogenous or exposure
variables such as smoking or diet may account for the difference in
genomic abnormalities, although there is no evidence that such
environmental factors impact on the pattern of chromosomal
aberrations in breast carcinomas.
In conclusion, our study significantly adds to the existing body
of knowledge by (a) detailing a number of previously undescribed
recurrent chromosomal gains and losses in premenopausal breast
cancers; (b) focusing on a unique cohort of breast carcinomas
associated with prolonged low-dose radiation exposure; and (c)
describing a set of CNAs that are specific to tumours from
a nuclear fallout area. Our findings may provide the basis for
future studies on the molecular pathogenesis of early-onset breast
cancer.
ACKNOWLEDGEMENTS
This work was supported in part by Grant No. N00014-94-1-0049,
issued to Georgetown University from the Office of Naval Research
in support of the International Consortium for Research on the
Health Effects of Radiation. The contents are solely the respon-
sibility of the authors and do not represent the views of the Office
of Naval Research, Georgetown University, or the International
Consortium for Research on the Health Effects of Radiation. This
study was also supported by shared resources of the Roswell Park
Cancer Center Support Grant P30 CA16056 and by a UICC
International Cancer Technology Transfer Fellowship (to A
Pryshchepava).
REFERENCES
Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D,
Kuo WL, Gray JW, Pinkel D (2000) Quantitative mapping of amplicon
structure by array CGH identifies CYP24 as a candidate oncogene.
Nat Genet 25: 144–146
Aubele M, Cummings M, Walsch A, Zitzelsberger H, Nahrig J, Hofler H,
Werner M (2000a) Heterogeneous chromosomal aberrations in intra-
ductal breast lesions adjacent to invasive carcinoma. Anal Cell Pathol 20:
17–24
Aubele MM, Cummings MC, Mattis AE, Zitzelsberger HF, Walch AK,
Kremer M, Hofler H, Werner M (2000b) Accumulation of chromosomal
imbalances from intraductal proliferative lesions to adjacent in situ and
invasive ductal breast cancer. Diagn Mol Pathol 9: 14–19
Behrens C, Travis LB, Wistuba II, Davis S, Maitra A, Clarke EA,
Lynch CF, Glimelius B, Wiklund T, Tarone R, Gazdar AF (2000)
Molecular changes in second primary lung and breast cancers after
therapy for Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev 9:
1027–1035
Clemons M, Loijens L, Goss P (2000) Breast cancer risk following
irradiation for Hodgkin’s disease. Cancer Treat Rev 26: 291–292
Cowell JK, Matsui S, Wang YD, LaDuca J, Conroy J, McQuaid D, Nowak NJ
(2004a) Application of bacterial artificial chromosome array-
based comparative genomic hybridization and spectral karyotyping to
the analysis of glioblastoma multiforme. Cancer Genet Cytogenet 151:
36–51
Table 6 Genetic changes distinguishing premenopausal breast cancers from WNY and Gomel, Belarus
WNY Belarus
BAC clone (RP11-) Chr. loc. Candidate genes Ampl. Del. Ampl. Del.
425I11 8q21.3 DECR1, C8orf1 9 2
122C21 8q21.3 CBFA2T1 6 2
157P1 20q13.33 OSBPL2, ADRM1, LAMAS 0 8
148K15 1q32.1 MDM4 0 6
461N23 13q32.3 EBI2, GPR18 0 6
150L7 1q32.1 PKP1 0 5
243M13 1q32.1 CNTN2, RBBP5, ABO18299 0 5
455F5 16p11.2 SULT1A3, ALDOA, TBX6, CORO1A, MGC5178 0 5
465L10 20q13.12 PLTP, ZNF335, SLC12A5, NCOA5 0 5
252A24 16q22.3 PSMD7, GLG1 0 6 3 1
2I16 5q35.3 COL23A1 1 4 5 0
58M17 16p13.2 USP7 0 3 4 0
73F15 17q11.2 CRLF3 6 0
126L15 7q22.1 ZAN, EPHB4, ACHE 3 0
211E17 11p15.4 TRIM3, ILK, TAF10, CLN2, PCDH16 3 0
35J17 19q13.42 ZNF331 3 0
571M6 12q14.1 CDK4 3 0
746M1 17p11.2 USP22, DKFZp5660084, C17orf35 3 0
36J16 17q21.32 NDP52, HOXB13 8 2
208J12 17p13.2 TRV1, CARKL, CTNS 8 2
61B16 17p13.3 CT120, GEMIN4 8 3
213L15 22q12.1 KREMEN1 6 1
2J15 19q13.32 CALM 3, PTIGR, GNG8 6 1
89M8 8p21.2 RHOBTBN2, TNFRSF10B 6 1
298C17 19p13.2 EIF3S4, DNMT1, P2RY11 6 1
WNY¼Western New York; Chr. loc.¼chromosomal location; Ampl.¼amplification; Del.¼deletion. In all, 25 (out of 50) distinguishing BAC clones contained named genes
(listed). Ten BAC clones (bold) were selectively amplified in Belarussian breast cancers and may represent signature events related to radiation exposure.
Array CGH analysis of premenopausal breast cancer
G Varma et al
707
British Journal of Cancer (2005) 93(6), 699–708 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sCowell JK, Nowak NJ (2003) High-resolution analysis of genetic events in
cancer cells using bacterial artificial chromosome arrays and compara-
tive genome hybridization. Adv Cancer Res 90: 91–125
Cowell JK, Wang YD, Head K, Conroy J, McQuaid D, Nowak NJ (2004b)
Identification and characterisation of constitutional chromosome
abnormalities using arrays of bacterial artificial chromosomes. Br J
Cancer 90: 860–865
Durante M, Grossi GF, Yang TC (1996) Radiation-induced chromosomal
instability in human mammary epithelial cells. Adv Space Res 18: 99–108
Ermak G, Figge JJ, Kartel NA, Davies KJA (2003) Genetic aberrations in
Chernobyl-related thyroid cancers: Implications for possible future
nuclear accidents or nuclear attacks. IUBMB Life 55: 637–641
Gaffney DK, Hemmersmeier J, Holden J, Marshall J, Smith LM, Avizonis V,
Tran T, Neuhausen SL (2001) Breast cancer after mantle irradiation for
Hodgkin’s disease: correlation of clinical, pathologic, and molecular
features including loss of heterozygosity at BRCA1 and BRCA2. Int J
Radiat Oncol Biol Phys 49: 539–546
Hildebrandt MA, Salavaggione OE, Martin YN, Flynn HC, Jalal S, Wieben
ED, Weinshilboum RM (2004) Human SULT1A3 pharmacogenetics: gene
duplication and functional genomic studies. Biochem Biophys Res
Commun 321: 870–878
Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E,
Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP,
Kallioniemi A (2002) Impact of DNA amplification on gene expression
patterns in breast cancer. Cancer Res 62: 6240–6245
Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK,
Waldman FM (1995) Genetic aberrations detected by comparative
genomic hybridization predict outcome in node-negative breast cancer.
Am J Pathol 147: 905–911
Kauraniemi P, Ba ¨rlund M, Monni O, Kallioniemi A (2001) New amplified
and highly expressed genes discovered in the ERBB2 amplicon in breast
cancer by cDNA microarrays. Cancer Res 61: 8235–8240
Kuukasja ¨rvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N,
Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J (1997) Genetic
heterogeneity and clonal evolution underlying development of asyn-
chronous metastasis in human breast cancer. Cancer Res 57: 1597–1604
Lage JM, Leamon JH, Pejovic T, Hamann S, Lacey M, Dillon D, Segraves R,
Vossbrinck B, Gonzalez A, Pinkel D, Albertson DG, Costa J, Lizardi PM
(2003) Whole genome analysis of genetic alterations in small DNA
samples using hyperbranched strand displacement amplification and
array-CGH. Genome Res 13: 294–307
Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I,
Tokuoka S (2003) Incidence of female breast cancer among atomic bomb
survivors, Hiroshima and Nagasaki, 1950–1990. Radiat Res 160: 707–717
Mahoney MC, Lawvere S, Falkner KL, Averkin YI, Ostapenko VA, Michalek
AM, Moysich KB, McCarthy PL (2004) Thyroid cancer incidence
trends in Belarus: examining the impact of Chernobyl. Int J Epidemiol
33: 1025–1033
Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe
D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are
Dickkopf receptors that regulate Wnt/beta-catenin signaling. Nature 417:
664–667
Peterson LE, Dreyer ZE, Plon SE, Smith JL, Weinberg A, McCarthy P (1997)
Design and analysis of epidemiological studies of excess cancer among
children exposed to Chernobyl radionuclides. Stem Cells 15(Suppl. 2):
211–230
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo
WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG
(1998) High resolution analysis of DNA copy number variation using
comparative genomic hybridization to microarrays. Nat Genet 20:
207–211
Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani
R, Botstein D, Borresen-Dale AL, Brown PO (2002) Microarray analysis
reveals a major direct role of DNA copy number alteration in the
transcriptional program of human breast tumors. Proc Natl Acad Sci USA
99: 12963–12968
Roy D, Calaf G, Hei TK (2001) Profiling of differentially expressed genes
induced by high linear energy transfer radiation in breast epithelial cells.
Mol Carcinogen 31: 192–203
Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J,
Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A,
Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A,
Trush V, Quackenbush J (2003) TM4: a free, open-source system
for microarray data management and analysis. Biotechniques 34:
374–378
Sasnouskaya A, Okeanov A (2000) Breast cancer incidence in Mogilev
Oblast after the Chernobyl accident. Zdravoohranenije (Publ Health) 10:
26–28
Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J,
Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J,
Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, Albertson DG (2001)
Assembly of microarrays for genome-wide measurement of DNA copy
number. Nat Genet 29: 263–264
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP
(1998) Molecular cytogenetics of primary breast cancer by CGH. Genes
Chromosom Cancer 21: 177–184
Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE,
Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van’t
Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice Jr
JD, Gilbert E (2003) Breast cancer following radiotherapy and
chemotherapy among young women with Hodgkin disease. JAMA 290:
465–475
Tuttle RM, Becker DV (2000) The Chernobyl accident and its consequences:
update at the millennium. Semin Nucl Med 30: 133–140
Wazer DE, Chu Q, Liu X-L, Gao Q, Safaii H, Band V (1994) Loss of p53
protein during radiation transformation of primary human mammary
epithelial cells. Mol Cell Biol 14: 2468–2478
Yang TC, Georgy KA, Craise LM, Durante M (1997) Initiation of oncogenic
transformation in human mammary epithelial cells by charged particles.
Radiat Oncol Invest 5: 134–138
Zudaire I, Odero MD, Caballero C, Valenti C, Martinez-Penuela JM, Isola J,
Calasanz MJ (2002) Genomic imbalances detected by comparative
genomic hybridization are prognostic markers in invasive ductal breast
carcinomas. Histopathology 40: 547–555
Array CGH analysis of premenopausal breast cancer
G Varma et al
708
British Journal of Cancer (2005) 93(6), 699–708 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s